Plus   Neg

Endocyte: Phase 2b TARGET Trial Results Show Improved Survival In NSCLC Patients

Endocyte, Inc. (ECYT) announced that the small molecule drug conjugate or SMDC vintafolide in combination with docetaxel extended overall survival or OS for patients with folate receptor or FR positive recurrent non-small cell lung cancer or NSCLC compared with patients receiving monotherapy docetaxel in its TARGET Phase 2b study. The late-breaking TARGET trial data would be presented at the European Society for Medical Oncology Congress or ESMO, by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.

The data show that patients in the predefined adenocarcinoma subgroup treated with the vintafolide plus docetaxel combination had a 27 percent reduction in risk of the disease worsening or death, and a 30 percent reduction in the risk of death compared to docetaxel monotherapy.

Rohit Lal said, "These results are very promising for patients receiving second-line treatment for this challenging disease. The folate receptor is a promising target, particularly in NSCLC, where the majority of patients are positive for this receptor. In particular, the consistency of results among patients with adenocarcinoma, including improved tumor response, delayed disease progression, and extended overall survival, support continued study of vintafolide in this patient population."

The study enrolled and treated 199 patients whose target tumors were all positive for the folate receptor, as determined with the companion imaging agent etarfolatide. Patients were randomized between three arms: vintafolide monotherapy, a combination of vintafolide and docetaxel, and docetaxel monotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The U.S. Department of Transportation or DOT is scrutinizing the development of Boeing 737 Max jetliners that were involved in two fatal crashes in five months, the Wall Street Journal reported Sunday, citing people familiar with the matter. Shares of Boeing are declining more than 2 percent in the regular trading session following the report. Shares of Worldpay, Inc. were gaining around 12 percent in London after the eCommerce and payments technology company announced its agreement to be merged with FIS, a U.S. financial services technology company. The combination of stock and cash values Worldpay at an enterprise value of approximately $43 billion, including the assumption of Worldpay debt. Germany's two biggest lenders, Deutsche Bank (DB) and Commerzbank (CRZBY.PK) Sunday confirmed they are in discussions to potential merge.
Follow RTT